S1: Financial and operational highlights:
– Revenue increased by 15%, with core operating income up 27%.
– Core margin reached 42.1%, indicating an increase of 400 basis points.
– Strong growth in key brands, including Kisqali (56% growth), Kesimpta (41% TRx growth), Pluvicto (21%), Lexio (72%), and Cosentyx (18%).
– Strong free cash flow of $3.4 billion, up 66%.
– Research & Development and marketing expenses are being reinforced, along with a $23 billion investment to expand U.S.-based manufacturing and R&D.
– Total sales growth achieved across multiple drug segments, particularly highlighting breast cancer, B-cell, MS, and cholesterol-lowering treatments.
S2: Market Expansion:
– Expansion and growth across U.S., European, and Asian markets, including Japan and China.
– Focus on expanding the use of Pluvicto into the PSMA-4 and PSMA-Addition populations, with over 620 centers now offering the therapy.
S3: Strategic cooperation:
– Acquired Anthos Therapeutics to strengthen cardiovascular portfolio.
– Emphasis on expanding partnerships to support strategic goals and broaden reach.
S4: New Product Launch:
– Recent approvals for Pluvicto, Venrafia, and Fopalta.
– Global submission completed for Remibrutinib in CSU.
– Ongoing launches in indications like HS and IV for specific brands.
S5: Management Change:
– No specific management changes were discussed during the call.
S6: Next quarter forward-looking estimates by management team:
– Raised full-year guidance to high single-digit growth in sales and low double-digit growth in core operating income.
– Continued growth expected, driven by brand performance and favorable gross to net adjustments.
– Plans to continue expanding manufacturing in the U.S. while managing the impact of expected generic entries for key drugs.